Skip to main content
SpringerLink
Log in

Invasive Carcinomas

  • Chapter
  • First Online:
Diagnosis and Management of Breast Tumors

  • 2186 Accesses

Abstract

Invasive, or infiltrating, ductal carcinoma (IDC) accounts for the majority (up to 80%) of breast cancers, with invasive lobular carcinoma (ILC) less common. There are pure histologic subtypes of IDC (such as mucinous, papillary, medullary, tubular), or tumors may be deemed “not otherwise specified,” or mixed, the details of which are deferred to the pathologists in other sections of this book. Ultimately, tumors are triaged by (and prognosis is based on) size, grade, marker status, molecular phenotype, and nodal status. However, with a basic, practical understanding of the pathology, one may be able to predict some of the nuances of histology based on imaging features. A few imaging descriptions and examples of the most common types and subtypes are provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69.

    Article  PubMed  Google Scholar 

  2. Barlow WE, Lehman CD, Zheng Y, et al. Performance of diagnostic mammography for women with signs or symptoms of breast cancer. J Natl Cancer Inst. 2002;94:1151.

    Article  PubMed  Google Scholar 

  3. Chang JH, Vines E, Bertsch H, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer. 2001;91:1231.

    Article  CAS  PubMed  Google Scholar 

  4. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790–800.

    Article  CAS  PubMed  Google Scholar 

  5. Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929.

    PubMed  PubMed Central  Google Scholar 

  6. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for treatment of invasive breast cancer. N Engl J Med. 2002;347:1233.

    Article  PubMed  Google Scholar 

  7. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778.

    Article  PubMed  Google Scholar 

  8. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796.

    Article  Google Scholar 

  9. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. J Clin Oncol. 2015;33(1):13.

    Article  CAS  PubMed  Google Scholar 

  10. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomized phase 2 trial. Lancet Oncol. 2014;15(7):747.

    Article  Google Scholar 

  11. Petrelli F, Borgonovo K, Cabiddu M, et al. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anti-Cancer Drugs. 2011;22:128.

    Article  CAS  PubMed  Google Scholar 

  12. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neosphere): a randomised multicenter, open-label, phase2 trial. Lancet Oncol. 2012;13:25.

    Article  CAS  PubMed  Google Scholar 

  13. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278.

    Article  CAS  PubMed  Google Scholar 

  14. A Study of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE). ClinicalTrials.gov. Identifier: NCT01772472.

  15. Platinum based chemotherapy or capecitabine in treating patients with residual triple-negative basal-like breast cancer following neoadjuvant chemotherapy. ClinicalTrials.gov. Identifier: NCT02445391.

  16. A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). ClinicalTrials.gov. Identifier: NCT01864746.

  17. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784.

    Article  CAS  PubMed  Google Scholar 

  18. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432.

    Article  Google Scholar 

  19. Henry NL, Somerfield MR, Abramson VG, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American Society of Clinical Oncology endorsement of Cancer Care Ontario guideline recommendations. J Clin Oncol. 2016;34:2303.

    Article  PubMed  Google Scholar 

  20. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817.

    Article  CAS  PubMed  Google Scholar 

  21. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55.

    Article  CAS  PubMed  Google Scholar 

  24. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999.

    Article  PubMed  Google Scholar 

  25. Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717.

    Article  CAS  PubMed  Google Scholar 

  26. Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: ABC trials- USOR 06-090, NSABP B-46-I/USOR 07132 and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017; doi:10.1200/JCO.2016.71.4147.

  27. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382:1021.

    Article  CAS  PubMed  Google Scholar 

  28. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012:CD006243. doi:10.1002/14651858.CD006243.pub2.

  29. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436.

    Article  PubMed  Google Scholar 

  32. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Goss PE, Inge JN, Pritchard KI, et al. Extending adjuvant aromatase-inhibitor therapy to 10 years. N Engl J Med. 2016;375:209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961.

    Article  CAS  PubMed  Google Scholar 

  36. Friedenreich CM, Gregory J, Kopciuk KA, et al. Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer. 2009;124:1954.

    Article  CAS  PubMed  Google Scholar 

  37. Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study. J Clin Oncol. 2010;28:4410.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Aebi S, Gelber S, Anderson SJ, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014;15:156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197.

    Article  CAS  PubMed  Google Scholar 

  40. Pusztai L, Viale G, Kelly CM, et al. Estrogen and HER2 receptor discordance between primary breast cancer and metastasis. Oncologist. 2010;15:1164.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277.

    Article  CAS  PubMed  Google Scholar 

  42. Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18:3758.

    Article  CAS  PubMed  Google Scholar 

  44. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009:CD003070. doi:10.1002/14651858.CD003370.pub3.

  45. Robertson JF, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388:2997.

    Google Scholar 

  46. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367:435.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925.

    Article  CAS  PubMed  Google Scholar 

  48. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738.

    Article  CAS  PubMed  Google Scholar 

  49. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520.

    Article  CAS  PubMed  Google Scholar 

  50. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109.

    Article  CAS  PubMed  Google Scholar 

  51. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35:141.

    Article  PubMed  Google Scholar 

  54. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733.

    Article  CAS  PubMed  Google Scholar 

Suggested Readings for the Radiology Section

  1. Cardenosa G. Clinical breast imaging: the essentials. Philadelphia, PA: Wolters Kluwer; 2015.

    Google Scholar 

  2. Lamb PM, Perry NM, Vinnicombe SJ, Wells CA. Correlation between ultrasound characteristics, mammographic findings and histologic grade in patients with invasive ductal carcinoma of the breast. Clin Radiol. 2000;55(1):40–4. doi:10.1053/crad.1999.0333. Accessed 26 Feb 2017.

    Article  CAS  PubMed  Google Scholar 

  3. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology. 2009;250(3):638–47. doi:10.1148/radiol.2503081054. Accessed 23 Feb 2017.

    Article  PubMed  Google Scholar 

  4. Trop I, LeBlanc SM, Davie J, et al. Molecular classification of infiltrating breast cancer: toward personalized therapy. Radiographics. 2014;34:1178–95.

    Article  PubMed  Google Scholar 

  5. Bae MS, Shin S, Ryu HS, et al. Pretreatment MR imaging features of triple-negative breast cancer: association with response to neoadjuvant chemotherapy and recurrence free survival. Radiology. 2016;281(2):392–400. doi:10.1148/radiol.2016152331. Accessed 23 Feb 2017.

    Article  PubMed  Google Scholar 

  6. Cardenosa G, Doudna C, Eklund GW. Mucinous (colloid) breast cancer: clinical and mammographic findings in 10 patients. AJR Am J Roentgenol. 1994;162:1077–9. doi:10.2214/ajr.162.5.8165985. Accessed 23 Feb 2017.

    Article  CAS  PubMed  Google Scholar 

  7. Liu H, Tan H, Cheng Y, et al. Imaging findings in mucinous breast carcinoma and correlating factors. Eur J Radiol. 2011;80(3):706–12. doi:10.1016/j.ejrad.2010.06.008. Accessed 23 Feb 2017.

    Article  PubMed  Google Scholar 

  8. Eiada R, Chong J, Kulkarni S, et al. Papillary lesions of the breast: MRI, ultrasound, and mammographic appearances. AJR Am J Roentgen. 2012;198:264–71.

    Article  Google Scholar 

  9. Mann RM, Hoogeveen YL, Blickman JG, et al. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat. 2008;107:1. doi:10.1007/s10549-007-9528-5. Accessed 23 Feb 2017.

    Article  PubMed  Google Scholar 

  10. Leddy R, Irshad A, Rumboldt T, et al. Review of metaplastic carcinoma of the breast: imaging findings and pathologic features. J Clin Imaging Sci. 2012;2:21. www.ncbi.nlm.nih.gov/pmc/articles/PMC3352608/. Accessed 28 Jan 2017

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bartella L, Dershaw DD. Magnetic resonance imaging of the invasive breast carcinoma. In: Morris E, Liberman L, editors. Breast MRI: diagnosis and intervention. New York, NY: Springer; 2005.

    Google Scholar 

  12. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomized controlled trial. Lancet. 2010;375(9714):563–71.

    Article  PubMed  Google Scholar 

  13. Vapiwala N, Hwang WT, Kushner CJ, et al. No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy. Cancer. 2016. doi:10.1002/cncr.30479. Accessed 25 Feb 2017.

  14. Iaconni C, Galman L, Zheng J, et al. Multicentric cancer detected at breast MR imaging and not at mammography: important or not? Radiology. 2016;279(2). doi:10.1148/radiol.2015150796. Accessed 23 Feb 2017.

  15. Hollingsworth AB, Stough RG. Multicentric and contralateral invasive tumors identified with pre-op MRI in patients newly diagnosed with ductal carcinoma in situ of the breast. Breast J. 2012;18(5):420–7. doi:10.1111/j.1524-4741.2012.01273.x. Accessed 26 Feb 2017.

    Article  PubMed  Google Scholar 

  16. Fortune-Greeley AK, Wheeler SB, Meyer AM, et al. Preoperative breast MRI and surgical outcomes in elderly women with invasive ductal and lobular carcinoma: a population based study. Breast Cancer Res Treat. 2014;143:203. doi:10.1007/s10549-013-2787-4. Accessed 26 Feb 2017.

    Article  PubMed  Google Scholar 

  17. Alliance for Clinical Trials in Oncology, American College of Radiology Imaging Network Alliance A011104/ACRIN 6694. Effect of preoperative breast MRI on surgical outcomes, costs and quality of life of women with breast cancer NCI Version Date: 04/01/2013.

    Google Scholar 

  18. Orel SG, Schnall MD. MR Imaging of the Breast for the Detection, Diagnosis, and Staging of Breast Cancer. Radiology. 2001;220(1):13–30. doi 10.1148/radiology.220.1.r01jl3113. Accessed 6/2/17.

  19. Liu PF, Debatin JF, Caduff RF, et al. Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis. The British Journal of Radiology. 1998;71(845):501–509. doi 10.1259/bjr.71.845.9691895. Accessed 6/2/17.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Oncology, Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University Health (VCU HEALTH), Richmond, VA, USA

    Hetal Vachhani MD

  2. Department of Radiology, Breast Imaging Section, Virginia Commonwealth University Health (VCU HEALTH), Richmond, VA, USA

    Priti A. Shah MD

  3. Department of Pathology, Virginia Commonwealth University Health (VCU HEALTH), Richmond, VA, USA

    Valentina Robila MD, PhD & Michael O. Idowu MD, MPH

Authors
  1. Hetal Vachhani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Priti A. Shah MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valentina Robila MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael O. Idowu MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hetal Vachhani MD .

Editor information

Editors and Affiliations

  1. Department of Pathology, Virginia Commonwealth University Health (VCU HEALTH), Richmond, Virginia, USA

    Michael Ola Idowu

  2. Department of Radiology Breast Imaging Section, Virginia Commonwealth University Health (VCU HEALTH), Richmond, Virginia, USA

    Priti Anilkumar Shah

  3. Division of Hematology Oncology and Palliative Care, Department of Internal Medicine, Virginia Commonwealth University Health (VCU HEALTH), Richmond, Virginia, USA

    Mary Helen Hackney

  4. Department of Pathology, Virginia Commonwealth University Health (VCU HEALTH), Richmond, Virginia, USA

    Margaret Mary Grimes

  5. Division of Hematology Oncology, Department of Internal Medicine, Virginia Commonwealth University Health (VCU HEALTH), Richmond, Virginia, USA

    Charles Edward Geyer, Jr.

  6. Department of Radiation Oncology, Virginia Commonwealth University Health (VCU HEALTH), Richmond, Virginia, USA

    Douglas William Arthur

  7. Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University Health (VCU HEALTH), Richmond, Virginia, USA

    Harry Douglas Bear

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Vachhani, H., Shah, P.A., Robila, V., Idowu, M.O. (2018). Invasive Carcinomas. In: Idowu, M., et al. Diagnosis and Management of Breast Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-57726-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-57726-5_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-57725-8

  • Online ISBN: 978-3-319-57726-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation